Astrid Persson
1 – 8 of 8
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials
(2025) 12th Øresund Workshop on Radiotherapy
- Contribution to conference › Abstract
-
Mark
Prostate-specific antigen bounce after prostate ultra-hypofractionation: associations with 5-year outcomes in the phase 3 trial HYPO-RT-PC
- Contribution to journal › Published meeting abstract
-
Mark
Stereotactic Body Radiotherapy as Metastasis-Directed Therapy in Oligometastatic Prostate Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - Beyond the Abstract
(2025)
- Other contribution › Web publication
- 2024
-
Mark
Register data on long-term morbidity after prostate ultra-hypofractionation in the HYPO-RT-PC trial
- Contribution to journal › Published meeting abstract
-
Mark
Morbiditet från urinvägar och tarm enligt registerdata efter ultrahypofraktionerad strålbehandling för lokaliserad prostatacancer vid 10 år i HYPO-RT-PC-studien
(2024) Onkologidagarna 2024
- Contribution to conference › Poster
-
Mark
Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials
- Contribution to journal › Article
-
Mark
Register data on long-term morbidity after prostate cancer radiotherapy with ultra-hypofractionated (2.5 weeks) vs conventional (8 weeks) treatment schedules
(2024) U21 Health Sciences Group 2024 Doctoral Student Forum
- Contribution to conference › Poster
-
Mark
Register data support the long-term safety of the use of ultra-hypofractionated radiotherapy for localised prostate cancer previously seen in the phase 3 trial HYPO-RT-PC : ESTRO 2024 congress report
(2024)
- Other contribution › Web publication
